Why Molbio was up 15% — key fundamental triggers

Why Molbio was up 15% — key fundamental triggers 1. HDFC Mutual Fund bought ~2% stake — major immediate trigger HDFC Mutual Fund bought around 23 lakh shares, equivalent to 1.99% of Molbio, in a bulk deal worth roughly ₹302 crore, at about ₹1,315/share. This institutional buying was a major positive sentiment trigger for the stock. 2. Jefferies initiated coverage with ₹1,600 target Just one day earlier, Jefferies initiated coverage on Molbio with a Buy view and a ₹1,600 target. Jefferies highlighted Molbio's Truenat platform, its international opportunity and its pipeline of new products. The brokerage estimates FY26–FY29 revenue CAGR of ~22% and PAT CAGR of ~47%, with margin expansion driven by higher capacity utilisation and operating leverage. These are brokerage estimates, not company guidance. 3. Strong Q1 FY27 financial performance supports the story Molbio's Q1 FY27 consolidated numbers showed a sharp turnaround: Total income: ₹411.5 crore vs ₹100.5 crore YoY EBITDA: ₹103.7 crore vs ₹14.5 crore loss PAT: ₹52.7 crore vs ₹23.9 crore loss EBITDA margin: 25.2% The company attributed the growth primarily to higher Truenat test-kit consumption. 4. Truenat has a sizeable international installed base The company says more than 12,500 Truenat devices had been installed across 90+ countries as of March 2026. It is also expanding internationally in Africa, Southeast Asia and Latin America, while pursuing regulatory pathways in developed markets. 5. Product pipeline provides a longer-term growth narrative Molbio says it has 34 additional assays across 22 diseases in its pipeline, while expanding beyond infectious diseases into areas such as oncology and other non-communicable diseases.